Department of Hematology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
Department of Internal Medicine, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
Medicine (Baltimore). 2023 Aug 4;102(31):e34462. doi: 10.1097/MD.0000000000034462.
Polycythemia vera (PV) diagnosis remains a difficult task despite various updates in the 2016 World Health Organization (WHO) diagnostic criteria compared to 2008 criteria. This study aimed to examine the biochemical and clinical features of patients diagnosed with PV using the WHO 2016 criteria but would have been missed by the WHO 2008 criteria, and to ascertain the impact of the lowered thresholds on PV diagnosis. A total of 229 patients with suspected myeloproliferative neoplasms were included in this cross sectional study. The study group was divided with regard to hemoglobin values. Group A consisted of 126 patients with hemoglobin values of ≤ 18.5 g/dL in males and ≤ 16.5 g/dL in females. Group B comprised 103 patients with hemoglobin values of > 18.5 g/dL in males and > 16.5 g/dL in females. The number of PV diagnoses increased to 145 from 87 (increased by 66.67%) when the 2016 diagnostic criteria were employed rather that the 2008 criteria. Mean age and the frequency of female subjects were lower in Group A compared to Group B. The groups were similar in terms of chronic obstructive pulmonary disease/obstructive sleep apnea syndrome, spleen status, smoking status, and mean corpuscular volume, white blood count, neutrophil, eosinophil and platelet values. red blood cells and lactate dehydrogenase values were significantly higher, while lymphocyte counts were significantly lower in Group B. With the introduction of WHO 2016 criteria, we found a significant increase in the number of patients who were candidates for PV testing and were ultimately diagnosed with PV. These findings support the diagnostic value of the 2016 WHO criteria, and by extension, the lowered thresholds for detection of patients requiring further analysis.
真性红细胞增多症 (PV) 的诊断仍然是一项艰巨的任务,尽管与 2008 年标准相比,2016 年世界卫生组织 (WHO) 诊断标准已经进行了各种更新。本研究旨在检查使用 WHO 2016 标准诊断但可能被 WHO 2008 标准遗漏的 PV 患者的生化和临床特征,并确定降低阈值对 PV 诊断的影响。共有 229 名疑似骨髓增殖性肿瘤患者纳入本横断面研究。根据血红蛋白值将研究组分为两组。A 组包括 126 名男性血红蛋白值≤18.5 g/dL 和女性血红蛋白值≤16.5 g/dL 的患者。B 组包括 103 名男性血红蛋白值>18.5 g/dL 和女性血红蛋白值>16.5 g/dL 的患者。与 2008 年标准相比,当使用 2016 年诊断标准时,PV 诊断数量从 87 例增加到 145 例(增加了 66.67%)。与 B 组相比,A 组的平均年龄和女性患者比例较低。两组在慢性阻塞性肺疾病/阻塞性睡眠呼吸暂停综合征、脾脏状况、吸烟状况以及平均红细胞体积、白细胞计数、中性粒细胞、嗜酸性粒细胞和血小板值方面相似。红细胞和乳酸脱氢酶值明显较高,而淋巴细胞计数明显较低。随着 WHO 2016 标准的引入,我们发现有更多的患者适合进行 PV 检测,并最终被诊断为 PV。这些发现支持 2016 年 WHO 标准的诊断价值,进而支持降低检测需要进一步分析的患者的阈值。